Immucell Corp
ICCC- Exchange
- Nasdaq
- Industry
- In Vitro & In Vivo Diagnostic Substances
- SEC CIK
- 0000811641
No open-market purchases or sales by Immucell Corp insiders were filed in the last 90 days; 31 institutions reported holding it in 13F filings for Q2 2026, worth $13.4M in total; no superinvestor holds it.
Q3 2021 vs. Q2 2021
How the institutions holding Immucell Corp changed between Q2 2021 and Q3 2021.
All holders in Q3 2021All holders in Q2 2021
| Measure | Q2 2021 | Q3 2021 | Change |
|---|---|---|---|
| Holders | 28 | 28 | 0 |
| Shares | 784.7K | 862.8K | +78.1K (+9.9%) |
| Value | $7.45M | $8.05M | +$596.8K (+8.0%) |
New holders (3)
Institutions that held Immucell Corp at the end of Q3 2021 but not at the end of Q2 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Meristem Family Wealth, LLC | 85,519 | $790.0K | 0.08% |
| Essex Financial Services, Inc. | 14,000 | $131.0K | 0.01% |
| Koshinski Asset Management, Inc. | 2,900 | $26.8K | 0.00% |
Sold out (3)
Institutions that held Immucell Corp at the end of Q2 2021 and filed for Q3 2021 without it.
| Institution | Shares, Q2 2021 | Value, Q2 2021 |
|---|---|---|
| Mercer Global Advisors Inc | 11,202 | $106.0K |
| Envestnet Asset Management Inc | 11,202 | $106.0K |
| Tower Research Capital LLC (TRC) | 426 | $4.00K |